Scarica l'app Stockscreener
6.74
2.43%
0.16
Dopo l'orario di chiusura:
6.99
0.25
+3.71%
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Trevi Therapeutics Closes Public Offering - marketscreener.com
Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - PR Newswire
Trevi Therapeutics Secures Massive $115M Funding: Investors Rush to Back Chronic Cough Treatment Developer - Stock Titan
Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq
Trevi Therapeutics Announces Public Offering Pricing - TipRanks
Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress
Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com
H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada
Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - Insider Monkey
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey
Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada
Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa
Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa
Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India
Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks
Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK
Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com
Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus
Trevi Therapeutics launches $100 million stock offering - Investing.com
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus
Clinical-Stage Biotech Trevi Therapeutics Seeks $100M in Major Stock Offering with Morgan Stanley Leading - Stock Titan
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga
trevi therapeutics reports positive results from phase 2b cough trial - Investing.com Australia
trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Nigeria
Transcript : Trevi Therapeutics, Inc.Special Call - marketscreener.com
Trevi Therapeutics Reports Positive Phase 2b Trial Results - TipRanks
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Ca - GuruFocus
Trevi Therapeutics Announces Positive Topline Results From Phase 2B Coral Trial Of Haduvio - marketscreener.com
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Achieves Positive Results in Cough Treatment Trial | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - Longview News-Journal
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - The Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2 - GuruFocus
Critical Phase 2b Results Coming: Trevi's Novel IPF Chronic Cough Drug Could Change Treatment Landscape - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts - Defense World
What is HC Wainwright’s Forecast for TRVI Q2 Earnings? - Defense World
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating - MSN
Trevi Therapeutics to Participate in Upcoming June Conferences | - GuruFocus
Trevi Therapeutics to Participate in Upcoming June Conferences - Citizen Tribune
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright Commences Coverage on Trevi Therapeutics (TRVI) with Positive Outlook | TRVI Stock News - GuruFocus
H.C. Wainwright sets $21 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Trevi Therapeutics (TRVI) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $21 target for Trevi Therapeutics stock - Investing.com
HC Wainwright & Co. Initiates Coverage on Trevi Therapeutics (TRVI) with Buy Rating | TRVI Stock News - GuruFocus
Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
0.86%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):